Show simple item record

dc.contributor.authorHuis In 't Veld, EAen_US
dc.contributor.authorGrünhagen, DJen_US
dc.contributor.authorVerhoef, Cen_US
dc.contributor.authorSmith, HGen_US
dc.contributor.authorvan Akkooi, ACJen_US
dc.contributor.authorJones, Ren_US
dc.contributor.authorvan Coevorden, Fen_US
dc.contributor.authorHayes, AJen_US
dc.contributor.authorvan Houdt, WJen_US
dc.coverage.spatialEnglanden_US
dc.date.accessioned2018-02-15T16:02:15Z
dc.date.issued2017-11en_US
dc.identifierhttps://www.ncbi.nlm.nih.gov/pubmed/28918185en_US
dc.identifierS0959-8049(17)31143-7en_US
dc.identifier.citationEur J Cancer, 2017, 85 pp. 114 - 121en_US
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/1138
dc.identifier.eissn1879-0852en_US
dc.identifier.doi10.1016/j.ejca.2017.07.023en_US
dc.description.abstractBACKGROUND: Angiosarcomas are rare and aggressive soft-tissue sarcomas. The only potential curative treatment is complete surgical excision. This study reports the outcome of isolated limb perfusion (ILP) with high-dose melphalan and tumour necrosis factor α for locally advanced angiosarcoma. MATERIAL AND METHODS: All patients who underwent an ILP for angiosarcomas between 1991 and 2016 in three tertiary referral centres were identified from prospectively maintained databases. RESULTS: A total of 39 patients were included, with a median follow-up of 18 months (interquartile range 6.1-60.8). Of these patients, 23 (58.9%) patients had a complete response (CR) after ILP, 10 (25.6%) had a partial response, 4 (10.3%) had stable disease and 2 (5.1%) patients had progressive disease immediately after ILP. A total of 22 patients developed local progression (56.4%), whereas nine (23.1%) developed distant metastases. The patients with CR had a significantly prolonged median local progression-free survival (PFS) (15.4 versus 7.3 months, p = 0.015) when compared with non-CR patients, and a trend towards better median overall survival (81.2 versus 14.5 months, p = 0.054). Six patients underwent multiple ILPs, whereby the CR rate of the first, second and third ILPs were 60%, 80% and 67%, respectively. Thirteen (33.3%) patients needed further surgical intervention, consisting of resection in eight patients (20.5%) and amputation in five patients (12.8%). CONCLUSION: ILP is an effective treatment option for patients with locally advanced angiosarcoma in the extremities, resulting in a high number of CRs, a high limb salvage rate and prolonged local PFS.en_US
dc.format.extent114 - 121en_US
dc.languageengen_US
dc.language.isoengen_US
dc.subjectAngiosarcomaen_US
dc.subjectCutaneous angiosarcoma of the extremityen_US
dc.subjectILPen_US
dc.subjectIsolated limb perfusionen_US
dc.subjectLimb salvage techniqueen_US
dc.subjectLocally advanced angiosarcomaen_US
dc.subjectSarcomaen_US
dc.subjectAdulten_US
dc.subjectAgeden_US
dc.subjectAged, 80 and overen_US
dc.subjectAmputationen_US
dc.subjectAntineoplastic Combined Chemotherapy Protocolsen_US
dc.subjectChemotherapy, Cancer, Regional Perfusionen_US
dc.subjectDatabases, Factualen_US
dc.subjectDisease Progressionen_US
dc.subjectDisease-Free Survivalen_US
dc.subjectExtremitiesen_US
dc.subjectFemaleen_US
dc.subjectHemangiosarcomaen_US
dc.subjectHumansen_US
dc.subjectKaplan-Meier Estimateen_US
dc.subjectLimb Salvageen_US
dc.subjectLondonen_US
dc.subjectMaleen_US
dc.subjectMelphalanen_US
dc.subjectMiddle Ageden_US
dc.subjectNetherlandsen_US
dc.subjectProportional Hazards Modelsen_US
dc.subjectRegional Blood Flowen_US
dc.subjectRetreatmenten_US
dc.subjectRetrospective Studiesen_US
dc.subjectRisk Factorsen_US
dc.subjectSoft Tissue Neoplasmsen_US
dc.subjectTime Factorsen_US
dc.subjectTreatment Outcomeen_US
dc.subjectTumor Necrosis Factor-alphaen_US
dc.subjectYoung Adulten_US
dc.titleIsolated limb perfusion for locally advanced angiosarcoma in extremities: A multi-centre study.en_US
dc.typeJournal Article
dcterms.dateAccepted2017-07-18en_US
rioxxterms.versionofrecord10.1016/j.ejca.2017.07.023en_US
rioxxterms.licenseref.startdate2017-11en_US
rioxxterms.typeJournal Article/Reviewen_US
dc.relation.isPartOfEur J Canceren_US
pubs.notesNot knownen_US
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Sarcoma Clinical Trials (R Jones)
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Sarcoma Clinical Trials (R Jones)/Sarcoma Clinical Trials (R Jones) (hon.)
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Sarcoma and Melanoma Surgery
pubs.organisational-group/ICR/Primary Group/Royal Marsden Clinical Units
pubs.publication-statusPublisheden_US
pubs.volume85en_US
pubs.embargo.termsNot knownen_US
icr.researchteamSarcoma Clinical Trials (R Jones)en_US
icr.researchteamSarcoma and Melanoma Surgeryen_US
dc.contributor.icrauthorJones, Robinen_US
dc.contributor.icrauthorSmith, Henryen_US
dc.contributor.icrauthorHayes, Andrewen_US
dc.contributor.icrauthorMarsden,en_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record